All articles tagged with #cellular reprogramming
Scientists have begun the first human trial of partial cellular reprogramming to nudge aging eye cells toward a younger state in hopes of regenerating optic nerve neurons to treat glaucoma. The study by Life Biosciences treated the first participant and plans to enroll up to 12 total; this is an early, experimental approach—not a lifespans therapy—with cancer risk as a key concern and no results yet.
Scientists have treated the first participant in an early-stage clinical trial testing partial cellular reprogramming to make aging cells act younger, aiming to regenerate optic nerve neurons in glaucoma. While promising, the approach is experimental, enrolling up to 12 participants, with potential cancer risk, and is not a universal anti-aging therapy.
The first participant has been treated in a landmark trial testing partial cellular reprogramming—activating three genes to make aged cells behave younger—in hopes of regenerating optic nerve neurons and treating glaucoma; safety is the primary focus, with low—but not zero—risk of cancer, and results will determine viability for broader use.
Life Biosciences dosed the first patient in a human trial of ER-100, a cellular reprogramming therapy designed to make aging cells act younger; the injection targeted the eye for glaucoma and uses three of the Yamanaka factors with a doxycycline switch to control activity. If safe and effective, it could open the door to systemic anti-aging therapies, but cancer risk remains a concern. The study will monitor safety over six months with up to about 20 participants enrolled across multiple cities.
A recent review proposes the Information Theory of Aging (ITOA) to explore whether epigenetic reprogramming can restore youthful epigenetic information and reverse aging. The theory suggests that disturbances in the epigenome play a crucial role in aging and that epigenetic noise can accelerate the process. Studies have shown that aging is not only driven epigenetically but also reversible, and the review discusses the potential of epigenetic reprogramming to reverse age-related information loss. The ITOA makes predictions that in vivo epigenetic reprogramming might be able to reverse aging hallmarks, but further studies are needed to develop more accurate approaches to rejuvenate the epigenome and restore youthful tissue functions.
Geroscientist David Sinclair presents his "Information Theory of Aging," which argues that epigenetic changes, rather than DNA mutations, are the underlying cause of aging. The theory suggests that the loss of regulatory epigenetic information leads to cellular confusion and dysfunction, contributing to the manifestations of aging. Sinclair highlights the potential of cellular reprogramming techniques to reverse epigenetic dysregulation and rejuvenate cells. The theory draws inspiration from Claude Shannon's information theory of communication and proposes the existence of "passive" and "active" observer molecules that could preserve and correct epigenetic changes.
A study led by researchers at IRB Barcelona has found that vitamin B12 plays a crucial role in cellular reprogramming and tissue regeneration. The research showed that cellular reprogramming in mice requires large amounts of vitamin B12, and supplementation significantly enhanced the efficiency of the process. The study also demonstrated that vitamin B12 supplementation benefited intestinal cells involved in tissue repair, suggesting potential therapeutic applications for patients with ulcerative colitis. Additionally, another study by the same group linked higher levels of vitamin B12 to lower inflammation markers in humans and aged mice, highlighting the potential health benefits of the vitamin.
Researchers from MIT and Harvard have developed a groundbreaking computational approach that efficiently identifies optimal genetic interventions for cellular reprogramming. Leveraging cause-and-effect relationships within complex systems, the method uses active learning and output weighting to narrow down the search space and prioritize interventions most likely to lead to optimal outcomes. Practical tests with biological data showed superior interventions at every stage, suggesting that fewer experiments could yield the same or better results, reducing costs and enhancing efficiency. The technique has potential applications beyond genomics and could accelerate progress in immunotherapy and regenerative therapies.
Researchers from Harvard Medical School, the University of Maine, and MIT have made a groundbreaking discovery in cellular aging, developing a chemical method to reverse the aging process in human cells. The study identified six chemical combinations that could rejuvenate cells and return them to a youthful state, potentially offering an alternative to gene therapy for age reversal. The research opens up new possibilities for treating age-related diseases and could lead to whole-body rejuvenation.
The Curious Case of Benjamin Button, a science fiction movie, poses a unique question about reversing aging. Some anti-aging researchers are trying to answer this question through epigenetics, which refers to altering the activity of genes without changing the underlying DNA. Cellular reprogramming, which has its roots in epigenetics, is the idea that you can reprogram cells to an earlier stage in development to turn back the body’s epigenetic clock. However, researchers need to be cautious about such results, and no clinical human trials have been conducted. It is a technology that only the rich could afford, and it is still a long way from achieving such a drug. Instead of searching for a way to turn back the clock, researchers should focus on making aging a less painful experience.